BMRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding (end-of-period, EOP). Biomarin Pharmaceutical Inc's share price for the quarter that ended in Sep. 2016 was $92.52. Biomarin Pharmaceutical Inc's shares outstanding (EOP) for the quarter that ended in Sep. 2016 was 163 Mil. Therefore, Biomarin Pharmaceutical Inc's market cap for the quarter that ended in Sep. 2016 was $15,124 Mil.
Biomarin Pharmaceutical Inc's quarterly market cap declined from Mar. 2016 ($13,382 Mil) to Jun. 2016 ($12,703 Mil) but then increased from Jun. 2016 ($12,703 Mil) to Sep. 2016 ($15,124 Mil).
Biomarin Pharmaceutical Inc's annual market cap increased from Dec. 2013 ($10,092 Mil) to Dec. 2014 ($13,478 Mil) and increased from Dec. 2014 ($13,478 Mil) to Dec. 2015 ($16,922 Mil).
Enterprise value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biomarin Pharmaceutical Inc's enterprise value for Today is $13,780 Mil.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biomarin Pharmaceutical Inc's Market Cap for the fiscal year that ended in Dec. 2015 is calculated as
|Market Cap (A: Dec. 2015 )||=||Share Price (A: Dec. 2015 )||*||Shares Outstanding (EOP) (A: Dec. 2015 )|
Biomarin Pharmaceutical Inc's Market Cap for the quarter that ended in Sep. 2016 is calculated as
|Market Cap (Q: Sep. 2016 )||=||Share Price (Q: Sep. 2016 )||*||Shares Outstanding (EOP) (Q: Sep. 2016 )|
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biomarin Pharmaceutical Inc Annual Data
Biomarin Pharmaceutical Inc Quarterly Data